PA5-20333

antibody from Invitrogen Antibodies

Targeting: PTGDR2 CD294, CRTH2, DP2, GPR44

Western blot (Supportive data in Antibodypedia)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-20333

Provider

Invitrogen Antibodies

Product name

CRTH2 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

A suggested positive control is human heart tissue lysate. PA5-20333 can be used with blocking peptide PEP-0453.

Reactivity

Human, Mouse, Rat

Host

Rabbit

Isotype

IgG

Vial size

100 µg

Concentration

1 mg/mL

Storage

Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C

References

Submitted references

AMPK induces regulatory innate lymphoid cells after traumatic brain injury.

Baban B, Braun M, Khodadadi H, Ward A, Alverson K, Malik A, Nguyen K, Nazarian S, Hess DC, Forseen S, Post AF, Vale FL, Vender JR, Hoda MN, Akbari O, Vaibhav K, Dhandapani KM
JCI insight 2021 Jan 11;6(1)

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of human heart tissue lysate using a CD294/CRTH2 polyclonal antibody (Product # PA5-20333) at (A) 1 and (B) 2 µg/mL.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western Blot analysis of CRTH2 in human heart tissue lysate with CRTH2 Polyclonal Antibody (Product # PA5-20333) at (A) 1 and (B) 2 µg/mL.

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence of CRTH2 in Human Heart cells with CRTH2 Polyclonal Antibody (Product # PA5-20333) at 20 µg/mL.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 1 Presence and frequency of ILC subtypes within the meninges of severe TBI patients. ( A ) Dura was collected from consecutive, severe TBI patients undergoing decompressive craniectomy to alleviate elevated intracranial pressure. ILCs were sorted using forward scatter (FSC)/side scatter (SSC) and identified as CD45 + , lineage-negative (Lin - ), CD127 + lymphoid cells. ILCs subtypes were further defined as ILC1:, CD45 + Lin - CD127 + CD161 + NKp44 + ; ILC2, CD45 + Lin - CD127 + GATA3 + CRTH2 + ; and ILC3, CD45 + Lin - CD127 + RORgammat + AhR + , as shown in representative flow cytometry scatterplots. Gray shaded areas indicate isotype controls. To demonstrate functionality, ILCs were further stimulated with cytokine cocktails, and production of signature cytokines was assessed (ILC1, IFN-gamma; ILC2, IL-5/IL-13; ILC3, IL-17). ( B and C ) Frequency of ILC subtypes from individual patients, expressed as total cell number ( B ) and % leukocytes ( C ) ( n = 5). Scatterplots depict mean +- SD. ( D ) Computed tomography scan of a TBI patient before (Pre-) and after (Post-) decompressive craniectomy surgery. The dura was collected during surgery at the time of bone flap removal.